Skip to Main Content
Important information:
Important Information Regarding Medicare Advantage Plans – Learn More.
  • Sylvester Comprehensive Cancer Center |
  • Bascom Palmer Eye Institute
University of Miami Health
  • Appointments
  • Pay a Bill
  • Refer a Patient
  • International Patients
  • Donate Now
  • Search
  • Patient Login
  • Find a Doctor
  • Treatments Page 1
    Featured Treatments For
    • Allergy and Immunology
    • Arthritis (Rheumatology)
    • Bariatrics (Weight Loss Surgery)
    • Cancer (Oncology)
    • Cardiac and Vascular
    • Concierge Medicine
    • Dentistry
    • Dermatology
    • Diabetes
    • Ear, Nose, and Throat (ENT)
    • Emergency Care
    • Endocrinology, Diabetes and Metabolism
    • Executive Physicals
    • Eye Care (Ophthalmology)
    • Fertility Center
    • Gastrointestinal
    • Genetics
    • Geriatrics
    • Hepatology
    • High Blood Pressure (Hypertension)
    • Hyperbaric Oxygen Therapy
    • Infectious Diseases
    • Internal Medicine
    • Interventional Radiology
    • Lymphedema
    • Nephrology
    • Neurology
    • Neurosurgery
    • Obstetrics and Gynecology
    • Orthopaedics
    • Pain Management and Palliative Care
    • Pediatrics
    • Physical Medicine and Rehabilitation
    • Plastic Surgery
    • Primary Care
    • Psychiatry
    • Pulmonary Medicine
    • Radiology
    • Sleep Medicine
    • Sports Medicine Institute
    • Surgery
    • Transplant
    • UHealth Comprehensive Women’s Health Alliance
    • UHealth Premier
    • Urology
    View all Treatments
    Browse A-Z A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    Featured Treatments For
    • Allergy and Immunology
    • Arthritis (Rheumatology)
    • Bariatrics (Weight Loss Surgery)
    • Cancer (Oncology)
    • Cardiac and Vascular
    • Concierge Medicine
    • Dentistry
    • Dermatology
    • Diabetes
    • Ear, Nose, and Throat (ENT)
    • Emergency Care
    • Endocrinology, Diabetes and Metabolism
    • Executive Physicals
    • Eye Care (Ophthalmology)
    • Fertility Center
    • Gastrointestinal
    • Genetics
    • Geriatrics
    • Hepatology
    • High Blood Pressure (Hypertension)
    • Hyperbaric Oxygen Therapy
    • Infectious Diseases
    • Internal Medicine
    • Interventional Radiology
    • Lymphedema
    • Nephrology
    • Neurology
    • Neurosurgery
    • Obstetrics and Gynecology
    • Orthopaedics
    • Pain Management and Palliative Care
    • Pediatrics
    • Physical Medicine and Rehabilitation
    • Plastic Surgery
    • Primary Care
    • Psychiatry
    • Pulmonary Medicine
    • Radiology
    • Sleep Medicine
    • Sports Medicine Institute
    • Surgery
    • Transplant
    • UHealth Comprehensive Women’s Health Alliance
    • UHealth Premier
    • Urology
    View all Treatments
  • Locations
  • Patients & Families
    Quick links
    • Appointments
    • Pay a Bill
    • Make a Gift
    • Insurance Plans Accepted
    • MyUHealthChart
    • Advance Directives
    For Patients & Families
    • Your First Visit
    • Medical Records
    • Frequently Asked Questions
    • Patient and Caregiver Resources
    • Patients & Families
    • Public Transportation
    • UHealth Clinic at Walgreens
    • Classes & Events
    • Support Groups
    • Interpreter Services
    • International Patients
    • UMiami Health Talks
    About Uhealth
    • Why Choose UHealth
    • Benefits of an Academic Medical Center
    • Mission & Values
    • Leadership
    • Community Health Improvement
    • Nursing at UHealth
    • Health News
    • Miller School of Medicine
    • University of Miami
    • Careers
    • Volunteers
    • Contact Us
    Clinical Trials
    • Find a Clinical Trial
    • Understanding Clinical Trials
    • Clinical Trials FAQ's
    Traveling from overseas?
    We can help plan your visit. Learn More
    Quick links
    • Appointments
    • Pay a Bill
    • Make a Gift
    • Insurance Plans Accepted
    • MyUHealthChart
    • Advance Directives
    For Patients & Families
    • Your First Visit
    • Medical Records
    • Frequently Asked Questions
    • Patient and Caregiver Resources
    • Patients & Families
    • Public Transportation
    • UHealth Clinic at Walgreens
    • Classes & Events
    • Support Groups
    • Interpreter Services
    • International Patients
    • UMiami Health Talks
    About Uhealth
    • Why Choose UHealth
    • Benefits of an Academic Medical Center
    • Mission & Values
    • Leadership
    • Community Health Improvement
    • Nursing at UHealth
    • Health News
    • Miller School of Medicine
    • University of Miami
    • Careers
    • Volunteers
    • Contact Us
    Clinical Trials
    • Find a Clinical Trial
    • Understanding Clinical Trials
    • Clinical Trials FAQ's
Patient Login
  • University of Miami Health System
  • Clinical Trials
  • A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Principal Investigator

Carl Landgren

Enrollment Status

Closed

Clinical Trial ID

Institutional Protocol # 20210675
National Clinical Trials Identifier NCT03901963

Clinical Trial Summary

The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD)
negativity following the addition of daratumumab to lenalidomide relative to lenalidomide
alone, when administered as maintenance treatment to anti-cluster of differentiation 38
(CD38) treatment naive participants with newly diagnosed multiple myeloma who are MRD
positive as determined by next generation sequencing (NGS) at screening, following high-dose
therapy (HDT) and autologous stem cell transplant (ASCT).


Phase

Phase 3


Funding Agency/Sponsor

Industrial


Disease

Myeloma


Enrollment Eligibility

Inclusion Criteria:
- Must have newly diagnosed multiple myeloma with a history of a minimum of 4 cycles of
induction therapy, have received high-dose therapy (HDT) and autologous stem cell
transplantation (ASCT) within 12 months of the start of induction therapy, and be
within 6 months of ASCT on the date of randomization
- Must have a very good partial response (VGPR) or better response assessed per
International Myeloma Working Group (IMWG) 2016 criteria at the time of randomization
- Must have archived bone marrow samples collected before induction treatment (that is,
at diagnosis) or before transplant (for example, at the end of induction) or have
existing results on the index multiple myeloma clone based on Adaptive
Biotechnologies' next generation sequencing (NGS)-based minimal residual disease (MRD)
assay. Archived bone marrow samples will be used for calibration of myeloma clonal
cells to facilitate assessment of primary end point by NGS. If an existing result on
index myeloma clone is available from Adaptive Biotechnologies' NGS-based MRD assay,
as part of institutional procedures, an archived bone marrow sample is not required as
long as Adaptive Biotechnologies is able to retrieve historical results on the index
myeloma clone form the clinical database. Any one of the following archived samples
are required: (a) Greater than 1 milliliter (mL) viable frozen bone marrow aspirated
aliquot (preferred) collected in an ethylenediaminetetra-acetic acid (EDTA) tube,
frozen, and stored at a temperature of -80 centigrade (°C), or; (b) Non-decalcified
diagnostic bone marrow aspirate clot sections (block or slides) for MRD assessment:
(i) A formalin fixed paraffin embedded (FFPE) block of bone marrow aspirate clot, or
slides (preferably 5, if available), 5 micrometer each, of non-decalcified bone
marrow, or; (ii) Slides (preferably 5, if available), bone marrow aspirate smear;
(iii) Please note, bone marrow core sections are not acceptable samples for analysis;
(iv) In exceptional circumstances when index myeloma clone cannot be identified from
the archived bone marrow sample, a post-transplant sample can be used to identify
myeloma clone with permission from the sponsor
- Must have residual disease as defined by detectable MRD (Adaptive Biotechnologies' NGS
based MRD assay)
- Must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0,
1, or 2
Exclusion Criteria:
- A history of malignancy (other than multiple myeloma) unless all treatment of that
malignancy was completed at least 2 years before consent and the participant has no
evidence of disease before the of date of randomization. Exceptions are squamous and
basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, or other
non-invasive lesion that in the opinion of the investigator, with concurrence with the
sponsor's medical monitor, is considered cured with minimal risk of recurrence within
3 years
- Must not have progressed on multiple myeloma (MM) therapy at any time prior to
screening
- Have had prior treatment/therapy with: (a) Daratumumab or any other anti-cluster of
differentiation 38 (CD38) therapies, (b) Focal radiation therapy within 14 days prior
to randomization with the exception of palliative radiotherapy for symptomatic
management but not on measurable extramedullary plasmacytoma. Radiotherapy within 14
days prior to randomization on measurable extramedullary plasmacytoma is not permitted
even in the setting of palliation for symptomatic management, or (c) Plasmapheresis
within 28 days of randomization
- Be exhibiting clinical signs of meningeal or central nervous system involvement due to
multiple myeloma
- Have known chronic obstructive pulmonary disease (COPD) with a forced expiratory
volume in 1 second (FEV1) less than (<) 50 percent (%) of predicted normal
- Have known moderate or severe persistent asthma within the past 2 years or current
uncontrolled asthma of any classification
- Have any of the following: (a) Known history of seropositivity for human
immunodeficiency virus (HIV); (b) Seropositive for hepatitis B (defined by a positive
test for hepatitis B surface antigen [HBsAg]. Participants with resolved infection
(that is, participants who are HBsAg negative but positive for antibodies to hepatitis
B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs])
must be screened using real-time polymerase chain reaction (PCR) measurement of
hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded.
EXCEPTION: Participants with serologic findings suggestive of HBV vaccination
(anti-HBs positivity as the only serologic marker) AND a known history of prior HBV
vaccination, do not need to be tested for HBV DNA by PCR; (c) Seropositive for
hepatitis C (anti-hepatitis C virus [HCV] antibody positive or HCV-RNA quantitation
positive), except in the setting of a sustained virologic response, defined as
aviremia at least 12 weeks after completion of antiviral therapy)


Contact Information

Phone Number 305-243-2647
Get detailed information on ClinicalTrials.Gov

logo
alt="Twitter Logo">
USNWR Best Hospitals 2026-2027 USNWR Best Regional Hospitals 2026-2027
Quick links
  • Appointments
  • Find a Doctor
  • Pay a Bill
  • Insurance Plans Accepted
  • MyUHealthChart
  • Make a Gift
Patient & Families
  • Frequently Asked Questions
  • Medical Records
  • Interpreter Services
  • Clinical Trials
  • International Patients
  • UHealth Clinic at Walgreens
  • Support Groups
  • Price Transparency
  • Florida Health Finder
Healthcare Professionals
  • Refer a Patient
  • Physician & Executive Recruitment
  • Advanced Practice Providers
  • Immunology & Histocompatibility Laboratory
  • Nursing
  • Sleep Center
  • Sports Medicine Institute
  • Pathology Reference Services
About Uhealth
  • Why Choose UHealth
  • Benefits of an Academic Medical Center
  • Mission & Values
  • Leadership
  • Facts & Figures
  • Community Health Improvement
  • For Media
  • Miller School of Medicine
  • University of Miami
  • Careers
  • Volunteers
  • Supply Chain
  • Contact Us

Medical Disclaimer | Terms of Use | Privacy Statement | HIPAA Notice of Privacy Practices | Non-Discrimination Policy | No Surprises Billing Rights
© 2026 University of Miami Health System. All rights reserved.